TAG ARCHIVES FOR human subjects protections

3
Aug2021

On March 30, 2021, PRIM&R hosted the webinar “Ominum-Gatherum: An SBER Variety Show.” During this webinar, Tonya Ferraro, MEd, and Andrew Hedrick, MPA, CIP, focused on three social, behavioral, and educational research (SBER) topics: Terms of Service agreements, randomized controlled trials in the social sciences, and research involving deception.  Following the webinar, the presenters reflected on the session and prepared a guidance document for those working with SBER; we're pleased to share this resource with readers of Ampersand.  Read more

23
Jun2021

Are you an institutional official who works in research compliance, research integrity, human research subjects protection, animal care and use, or conflicts of interest compliance? You are invited to complete a short survey being conducted by researchers at Washington University School of Medicine. The Addressing Violations of Research Integrity and Compliance (AVRIC) study aims to understand institutional experiences and approaches to remediating research noncompliance or integrity violations. Read more

17
Jun2021

Human research rules have become a compliance bureaucracy, argues sociologist Sarah Babb in her 2020 book Regulating Human Research: IRBs from Peer Review to Compliance Bureaucracy, but that's not an inherently bad thing. The social and political climate the first research regulations were made in, and the enforcement mechanisms that would eventually take hold, have rationally led to the large and sophisticated bureaucracy that human research protections is today. Read more

11
Jun2021

The COVID-19 pandemic has brought to light, once again, the ongoing issue of racial health inequalities in the United States and around the globe. As the first vaccines and treatments for COVID-19 were being approved for use around the world, scrutiny of medical research and its oversight has highlighted the fact that there is still much to do to resolve the unending epidemic of racism in healthcare and to ensure diversity in clinical trials. Read more